KaloBios Raises $20 Million

KaloBios Pharmaceuticals Inc., a South San Francisco-based developer of antibody therapeutics, has raised $20 million in the first close of its Series D funding round. Mitsubishi UFJ Capital and Genzyme Corp. co-led the round, and were joined by return backers MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, Pte., 5AM Ventures and Lotus Bioscience Ventures.

North AmericaUSBriefs